Know Cancer

forgot password

Early Treatment With Deferasirox (Exjade®) in Low Risk MDS - a Prospective Multicentre Single-arm Single-stage Phase II Study -

Phase 2
18 Years
Not Enrolling
Myelodysplastic Syndromes

Thank you

Trial Information

Early Treatment With Deferasirox (Exjade®) in Low Risk MDS - a Prospective Multicentre Single-arm Single-stage Phase II Study -

Inclusion Criteria:

- MDS of subtype RA, RARS, RCMD, RCMD-RS (i.e. lower risk)

- RAEB I allowed, if clinically stable for > 3 months

- 5q-minus syndrome allowed, if lenalidomide unsuccessful or unavailable at the time of

- IPSS score < intermediate-1

- transfusion dependent or Hb < 10,5 g/dl

- History of less than 20 units of red blood cell transfusions or 100mL/kg of prepacked
red blood cells (PRBCs), except for transfusions for acute bleeding

- Serum ferritin > 300 µg/l and < 1500 μg/l. This level should have been verified at
least at two occasions within 3 months. Samples must be obtained in the absence of
concomitant severe infection

- no indication for EPO (due to high endogenous EPO levels) or EPO without benefit in
the past

- no indication and/or no plans for cytostatic drugs

- no previous exposure to cytostatic drugs, thalidomide, lenalidomide, G-CSF or EPO or
exposure to any of these drugs has been terminated since > 8 weeks (4 weeks for

- no indication and/or no plans for stem cell transplantation

- stable or worsening cytopenia during the past 8 weeks. If in doubt, extend screening
period to >= 8 weeks

- Patients of either gender and age > 18 years

- Life expectancy > 12 months

- Females of childbearing potential must use double-barrier contraception (for example
orale contraception and condom).

- Mental ability of the patient to understand explications concerning the study and to
understand and follow instructions of the investigating physician

- Written informed consent by the patient

Exclusion Criteria:

- Treatment with deferasirox or other chelation therapy for periods > 4 weeks before
study start

- Patients with intolerance to Deferasirox

- Patients with a concomitant second malignant disease, possibly interfering with life

- Patients with mean levels of alanine aminotransferase (ALT) > 5x ULN

- Patients with uncontrolled systemic hypertension

- Patients with serum creatinine > 1.5x the upper limit of normal (ULN) or a creatinine
clearance < 60 ml/min according to the MDRD formula (Levey 2005)

- History of nephrotic syndrome

- Systemic diseases (cardiovascular, renal, hepatic, etc.) which would prevent the
patient from undergoing study treatment

- Patients with psychiatric or addictive disorders which prevent them from giving their
informed consent or undergoing study treatment

- Patients treated with systemic investigational drugs within the past 4 weeks or
topical investigational drug within the past 7 days

- Any other surgical or medical condition which might significantly alter the
absorption, distribution, metabolism or excretion of any drug. The investigator
should be guided by evidence of any of the following:

- history of inflammatory bowel syndrome, gastritis, ulcers, gastrointestinal or rectal

- history of major gastrointestinal tract surgery such as gastrectomy,
gastroenterostomy, or bowel resection;

- history of pancreatic injury or pancreatitis; indications of impaired pancreatic
function/injury as indicated by abnormal lipase or amylase;

- history of urinary obstruction or difficulty in voiding

- History of non-compliance to medical regimens and patients who are considered
potentially unreliable and/or not cooperative

- History of drug or alcohol abuse within the 12 months prior to dosing or evidence of
such abuse as indicated by laboratory assays conducted during the screening period

- Patients with active uncontrolled infectious disease

- Pregnancy or breast feeding

- QT > 470 msec on screening ECG

- Patients with a history of Torsades de Pointes

Type of Study:


Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Fraction of patients with hematologic improvement according to modified IWG criteria (reduction of transfusions and/or increase in Hb, improvement of neutropenia and thrombocytopenia)

Outcome Time Frame:

within two years

Safety Issue:


Principal Investigator

Stefan Krause, Prof. Dr.

Investigator Role:

Study Chair

Investigator Affiliation:

Medizinische Klinik 5, Universitätsklinikum Erlangen


Germany: Federal Institute for Drugs and Medical Devices

Study ID:




Start Date:

April 2010

Completion Date:

January 2013

Related Keywords:

  • Myelodysplastic Syndromes
  • Myelodysplastic Syndromes
  • Preleukemia